Can you take Mirikizumab with Prasugrel?

Prasugrel has a major potential interaction with Bleeding Disorder.

Prasugrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage, as this agent increases the risk of fatal bleeding.

Prasugrel has a major potential interaction with Cerebrovascular Insufficiency.

Prasugrel is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke. Patients who experience a stroke or TIA while on prasugrel generally should have therapy discontinued. The risk of bleeding is increased in patients receiving prasugrel who undergo coronary artery bypass graft. If possible, prasugrel should be discontinued at least 7 days prior to the procedure.

Mirikizumab has a moderate potential interaction with Cirrhosis.

Mirikizumab can cause increased levels of liver enzymes and bilirubin. The effect of moderate to severe hepatic impairment on the pharmacokinetics of mirikizumab has not been evaluated. Other treatment options should be considered in patients with evidence of liver cirrhosis.

Mirikizumab has a moderate potential interaction with Infection.

Mirikizumab may increase the risk of infection. Patients should be evaluated for active infection before and during treatment with mirikizumab, and administration should be avoided if infection is detected.

Prasugrel has a major potential interaction with Ischemic Heart Disease.

Prasugrel is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke. Patients who experience a stroke or TIA while on prasugrel generally should have therapy discontinued. The risk of bleeding is increased in patients receiving prasugrel who undergo coronary artery bypass graft. If possible, prasugrel should be discontinued at least 7 days prior to the procedure.

Mirikizumab has a moderate potential interaction with Liver Disease.

Mirikizumab can cause increased levels of liver enzymes and bilirubin. The effect of moderate to severe hepatic impairment on the pharmacokinetics of mirikizumab has not been evaluated. Other treatment options should be considered in patients with evidence of liver cirrhosis.

Prasugrel has a moderate potential interaction with Liver Disease.

No dosage adjustment is necessary for patients with renal impairment. No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. Caution should be exercised in patients with end-stage renal disease and those with severe hepatic disease as such patients are generally at higher risk of bleeding.

Prasugrel has a moderate potential interaction with Renal Dysfunction.

No dosage adjustment is necessary for patients with renal impairment. No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. Caution should be exercised in patients with end-stage renal disease and those with severe hepatic disease as such patients are generally at higher risk of bleeding.

Mirikizumab has a moderate potential interaction with Tuberculosis, Active.

Patients treated with mirikizumab may be at increased risk for tuberculosis. Patients should be evaluated for TB before treatment with mirikizumab and therapy should be avoided in patients with active TB. Anti-TB therapy should be considered for patients with a history of latent or active TB.

Mirikizumab has a moderate potential interaction with Tuberculosis, Latent.

Patients treated with mirikizumab may be at increased risk for tuberculosis. Patients should be evaluated for TB before treatment with mirikizumab and therapy should be avoided in patients with active TB. Anti-TB therapy should be considered for patients with a history of latent or active TB.